Welcome to our dedicated page for Caris Life Sciences news (Ticker: CAI), a resource for investors and traders seeking the latest updates and insights on Caris Life Sciences stock.
Caris Life Sciences, Inc. develops and commercializes AI-enabled precision medicine solutions built around comprehensive molecular profiling, next-generation sequencing and machine learning. The company’s diagnostics and data platform use Whole Genome, Whole Exome and Whole Transcriptome Sequencing, a multimodal clinico-genomic database and high-performance computing to support early detection, diagnosis, monitoring, therapy selection and drug development.
Company announcements commonly address molecular profiling services, clinical therapy selection volume, product launches and regulatory or reimbursement actions for tests such as Caris Assure, Caris MI Clarity and Caris ChromoSeq. Other recurring developments include peer-reviewed validation of Caris AI Insights, Caris Precision Oncology Alliance collaborations, conference presentations and quarterly financial results.
Caris Life Sciences (NASDAQ: CAI) announced an interim readout of Achieve 1 for its Caris Detect multi-cancer early detection test on Feb 26, 2026. The interim dataset (2,122 samples) showed stage I sensitivity 56.8%, stage II 70.1%, and overall Stage I–II sensitivity 61.3%.
The study reported specificity 99.1% in an asymptomatic screening subgroup (n=121) and 95.3% in the undiagnosed population (n=1,505). A blinded validation (~865 samples) is in process with results expected later in Q1 2026.
Caris Life Sciences (NASDAQ: CAI) reported an interim readout of Achieve 1 for Caris Detect, its multi-cancer early detection blood test using ultra-deep Whole Genome Sequencing and AI. The interim dataset (n=2,122) showed Stage I sensitivity 56.8%, Stage I-II sensitivity 61.3% and specificity 99.1% in an asymptomatic screening subgroup.
Caris held ~865 samples for a blinded validation planned for Q1 2026; development of an updated assay with Whole Transcriptome Sequencing is underway.
Caris Life Sciences (NASDAQ: CAI) reported strong 2025 results with $812.0M revenue, up 97% year-over-year, and Q4 revenue of $292.9M (+125%). Gross margin improved to 66% for FY 2025. The company reported positive Adjusted EBITDA $137.7M and positive free cash flow $66.9M. Caris expects 2026 revenue of $1.0B–$1.02B and reiterated plans to launch Caris Detect in H1 2026.
Caris (NASDAQ: CAI) added a proprietary AI-driven breast cancer signature for capecitabine to its Caris Molecular Tumor Board Report, available with MI Cancer Seek. The signature uses more than 2,000 expression and copy-number features from WES and WTS to predict response in HER2-negative first-line breast cancer.
Caris noted MI Cancer Seek holds FDA approval (Nov 2024) as a WES/WTS-based tissue assay with companion diagnostic indications.
Caris Life Sciences (NASDAQ: CAI) will participate in the TD Cowen 46th Annual Health Care Conference held March 2-4, 2026 in Boston, Massachusetts. The company will present its precision medicine platform, AI/ML-enabled clinico-genomic capabilities, and recent corporate developments to investors and healthcare attendees.
Caris is headquartered in Irving, Texas, with global offices and provides comprehensive molecular profiling services including whole genome, whole exome and whole transcriptome sequencing.
Caris Life Sciences (NASDAQ: CAI) will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. A conference call and live webcast will be held at 3:30 p.m. CT (4:30 p.m. ET) to discuss the results.
Investors can join the live webcast at the provided media-server link and access a replay shortly after the call on the company's Investor Relations website.
Caris Life Sciences (NASDAQ: CAI) published a large real-world multiomic study (Jan 28, 2026) analyzing 2,799 trastuzumab deruxtecan (T‑DXd)–treated metastatic breast cancer patients. Whole transcriptome sequencing identified ERBB2 (HER2) and ABCC1 as the strongest transcriptomic predictors of T‑DXd–specific overall survival.
Higher ERBB2 expression aligned with better outcomes; higher ABCC1 correlated with poorer outcomes and increased post‑treatment, alongside enrichment of mutations in ERBB2, NFE2L2, KEAP1 and TOP1, suggesting evolving resistance pathways and actionable insights for drug development.
Caris Life Sciences (NASDAQ: CAI) reported preliminary, unaudited results for Q4 and full year 2025 showing strong growth driven by molecular profiling. For Q4 2025, total revenue was approximately $281 million (+116%), including ~$270 million from Molecular Profiling (with ~$81 million prior-period true-ups), and ~52,700 clinical therapy selection cases (+20%). For full year 2025, total revenue was approximately $800 million (+94%), including ~$755 million from Molecular Profiling (with ~$33 million prior-year true-ups), and ~199,300 cases (+22%). Preliminary cash and marketable securities were ~$802 million as of Dec 31, 2025. Results remain unaudited and subject to change; final results expected with the late-February 2026 earnings release.
Caris Life Sciences (NASDAQ: CAI) announced a partnership with Everlywell to launch Caris Detect, a forthcoming multi-cancer early detection (MCED) blood assay that uses whole genome sequencing (WGS) and AI-driven analysis to identify molecular signals in blood.
The collaboration will distribute Caris Detect via Everlywell's consumer platform and infrastructure; Caris expects to launch the assay in the first half of 2026. Everlywell cites broad reach, having delivered nearly 1 billion personalized health insights and served 60 million people.
Caris Life Sciences (NASDAQ: CAI) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, held January 12-15, 2026. Caris will present and participate in a Q&A session on Monday, January 12, 2026 at 1:30 PM PT.
Live and replay webcasts will be available on the Investor Relations section of Caris' website at CarisLifeSciences.com. The company is described as a patient-centric AI TechBio and precision medicine firm using whole exome and whole transcriptome sequencing plus AI to build a multimodal clinico-genomic database and computing platform.
Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge MA, Tokyo and Basel; media and investor contact emails are provided for inquiries.